前4个月我国汽车产销量首次双双突破1000万辆 "价格战"趋缓车市活力持续释放 中国汽车工业协会数据显示，今年4月，国内汽车产销量分别完成261.9万辆和259万辆，环比小幅回 落，同比保持近9%的增长。今年1—4月，我国汽车产销量历史上首次双双突破1000万辆。据统计，1— 4月，我国汽车产销量分别完成1017.5万辆和1006万辆，同比分别增长12.9%和10.8%。其中，新能源汽 车产销量分别完成442.9万辆和430万辆，同比分别增长48.3%和46.2%；新能源汽车新车销量达到汽车新 车总销量的42.7%。 中国汽车流通协会乘用车市场信息联席分会(以下简称乘联分会)相关负责人表示，今年车市"价格战"举 措稍显温和，但是诸如年款增配、调整车主权益等隐形优惠措施依然层出不穷。具体而言，在降价车型 数量方面，4月仅有14款车型降价，相较于去年4月的41款以及2023年4月的19款，降价车型数量大幅减 少，这充分体现出降价潮明显降温的特点。另外，4月传统燃油车的促销幅度为22.2%，较上月增长了 0.1%，且燃油车促销幅度已连续10个月稳定在22%左右。 相比之下，新能源车企更倾向于通过"增配不加价"的策略 ...

Core Viewpoint - The performance of major Chinese vaccine companies, including Wantai Biological Pharmacy (万泰生物), Zhifei Biological Products (智飞生物), and Watson Bio (沃森生物), has significantly declined in Q1 2025, primarily due to a shrinking self-paid market for HPV vaccines amid economic pressures [1] Group 1: Company Performance - Wantai Biological reported a revenue of 401 million yuan in Q1 2025, a year-on-year decrease of 46.76%, with a net loss of 52.78 million yuan [1] - Zhifei Biological's revenue fell to 2.374 billion yuan, down 79.16% year-on-year, resulting in a net loss of 305 million yuan [1] - Watson Bio achieved a revenue of 462 million yuan, a decline of 22.93%, with a net profit of 2.65 million yuan, down 81.27% [1] Group 2: Market Dynamics - The HPV vaccine market is experiencing a significant contraction, with a 61.57% year-on-year drop in the total number of HPV vaccine batches approved for sale in 2024 [3] - The two-valent HPV vaccine's sales revenue for Wantai Biological plummeted by 84.69% to 606 million yuan in 2024, influenced by price reductions and increased competition from the nine-valent HPV vaccine [3][4] - The price of HPV vaccines has drastically decreased, with the two-valent vaccine's procurement price dropping from over 300 yuan to 27.5 yuan in Shandong province, reflecting a nearly 90% decline [7] Group 3: Competitive Landscape - The introduction of the nine-valent HPV vaccine has intensified competition, with consumers favoring higher-priced vaccines, leading to a sharp decline in demand for the two-valent vaccine [4] - Zhifei Biological, as the exclusive agent for Merck's HPV vaccines, faced a 95.49% drop in the issuance of four-valent HPV vaccines in 2024, exacerbated by Merck's suspension of supplies to China [4][5] - The price war in the HPV vaccine market has severely compressed profit margins, with Wantai Biological's vaccine segment gross margin falling from 91.6% in 2022 to 70.4% in 2024 [7] Group 4: Future Outlook - The development of domestic nine-valent HPV vaccines is accelerating, with several companies, including Wantai Biological, advancing their clinical trials [8] - The potential introduction of male-targeted HPV vaccines may open new growth avenues, as Merck's four-valent HPV vaccine has been approved for male use [9]

以下文章来源于财经天下WEEKLY ，作者财经天下 财经天下WEEKLY . 《财经天下》周刊官方账号，提供有品质的深度报道，讲述中国企业在时代浪潮中的精彩故事。 本文转载自财经天下WEEKLY 值班编辑 | 江江 视觉 | 顾芗 给持续降价打了个幌子 "不用讨价还价，没有套路，奥迪A3限时一口价12.49万元起""奥迪A3低配贷款落地15万元，中配贷款落 地16万元"。进入5月，不少奥迪4S店的销售在社交媒体上吆喝了起来。 "奥迪的轿车都已经这么便宜了？"虽然有些消费者一开始抱有怀疑态度，但是当看到各路4S店官方账号 上放出的正式价格海报，也不禁感叹和调侃"奥迪这是卖出了奥拓的价格"。 目前在售的2025款奥迪A3同时提供两厢版和长轴距三厢版车型，其中两厢车型A3 Sportback共有"飞驰悦 享型""飞驰尊享型"以及"飞驰尊享型+豪华臻选包"3款车型，官方指导价分别为16.59万元、18.99万元和 20.59万元，三厢车型A3L Limousine也有同样的3款车型，官方指导价分别为16.99万元、19.39万元和 20.99万元。 在天津某奥迪4S店的宣传海报上，A3 Sportback降价后的"限 ...

618还没真正开始，整个机圈就已经非常热闹了。 当然，最大的热闹，自然还是苹果打价格战，特别是128G的iPhone16 Pro，直接降价至5999元，然后叠加国补，只要5499元了。 而一些电商平台，还有其它活动，再折扣优惠之后，甚至有些只要5399或更低了。 从去年iPhone16系列发布后，苹果在中国的销量就不行，特别是进入2025年之后，更是一路下滑，一季度，苹果在全球的收入都在涨，只有中国在下滑。 一时之间，iPhone16 Pro成为了当前最畅销的手机，没有之一。 不信大家看看京东的排行榜，截止至目前，累计销量iPhone16 Pro第一，iPhone16 Pro Max第二、iPhone16 第三名，销量最好的前五名，苹果占了前三名。 从这个情况来看，可见低价的苹果，多有威力了，而这其实也就是库克的阳谋，那就是我直接价格战开打，不玩虚的，没有阴谋，一把扯下苹果高高在上的 遮羞布，看国产手机怎么办？ 事实上，库克确实是被逼的没办法了， 不得不这么干。 所以接下来，在5000-8000档的国产机，真的是左右为难，降价跟苹果，那自己没赚钱，还影响品牌形象，不降价跟苹果，则没销量，真的是不知道怎么办 才 ...

以下文章来源于远川科技评论 ，作者徐珊珊/李墨天 远川科技评论 . 刻画这个时代（的前沿科技） 我是芯片超人花姐，入行20年，有50W+芯片行业粉丝。 有很多不方便公开发公众号的， 关于芯片买卖、关于资源链接等， 我会分享在朋友圈 。 大部分市场从群雄争霸走向寡头林立的过程中，价格战都无法避免。而当大鱼吃小鱼的游戏变成几条大白鲨大眼瞪小眼，价格战就会偃旗息鼓。 扫码加我本人微信 2024年，国内降价车型多达227款，是2023年1.5倍，2022年的2.3倍。 新能源爱好者买到了便宜的新能源汽车，旧能源拥护者买到了便宜的旧能源汽车；车企一边声嘶力竭地呼吁"从卷价格到卷价值"，一边给供应商发 邮件要求降价。 在"内卷"的语境下，"价格战"从一个商业现象变成了一个时代情绪的宣泄通道。但至少在汽车行业，惨烈的价格战在当下愈演愈烈，更多是产业发 展的必然结果。 内卷是一个社会问题，价格战是一个市场行为。汽车价格战的开始和结束，很难用"内卷"两个字完全概括。 01 和平戛然而止 制造业几乎所有价格战的出现，都源于 市场集中度 的变化。 内存芯片曾是价格战的重灾区，由于内存芯片高度标准化，竞争力完全锚定于成本，价格战往往 ...

Core Viewpoint - The intense competition in the food delivery market, driven by significant subsidies from Meituan, JD, and Taobao, has led to a price war that is reshaping consumer behavior and impacting platforms like Meituan's "Pin Hao Fan" [1][10][11] Group 1: Market Dynamics - The price war has resulted in lower delivery prices, attracting consumers who previously did not use delivery services, leading to a shift in purchasing habits among users [1][2] - Consumers are increasingly comparing prices across multiple platforms, with some finding that "Pin Hao Fan" offers higher prices for certain items compared to competitors [2][4] - The competition has affected "Pin Hao Fan" by drawing away some of its customer base, particularly in first and second-tier cities, although the impact is less pronounced in lower-tier cities [4][6][9] Group 2: Consumer Behavior - Different consumer segments exhibit varied responses to the price war, with some continuing to prefer "Pin Hao Fan" for its simplicity and low prices, while others are swayed by the competitive offers from other platforms [5][6] - The convenience of using "Pin Hao Fan" remains appealing to certain consumers, despite the ongoing price competition [5][10] Group 3: Business Impact - Merchants in second-tier cities report a slight decrease in "Pin Hao Fan" orders, but overall, the impact is not severe, indicating that the platform still retains a significant customer base [5][6][11] - The ongoing price competition is reshaping the pricing structure of the food delivery industry, with "Pin Hao Fan" potentially leading to a long-term reduction in average delivery prices [10][11] Group 4: Future Outlook - The growth of "Pin Hao Fan" and its increasing variety of offerings suggest that it may continue to attract more consumers, potentially reshaping the competitive landscape of food delivery [10][11] - The long-term implications of the price war may lead to reduced profitability for all players involved, with consumers benefiting in the short term from lower prices [11][12]

让未来不止于大 以下文章来源于字母榜 ，作者赵晋杰 两排西有奥特曼，东有梁文锋。 字母榜 . 文 ｜ 赵晋杰 编辑 ｜ 王靖 来源｜ 字母榜（ID：wujicaijing） 封面来源 ｜ DeepSeek官网 "无人不识梁文锋。" 从模型、应用到芯片，梁文锋携DeepSeek之威，掀起了一场波及全产业链的震荡。 这句话大概足以形容梁文锋今天在AI圈的地位：媒体想尽办法一访难求、投资人用尽手段一面难约。 DeepSeek爆红后，其研发团队所在的北京融科资讯中心和杭州汇金国际大厦，一段时间内挤满了媒体和投资人，甚至众多慕名而来的网友，直接将北京融 科资讯中心楼下的透明水牌，挤成了小红书上的网红打卡点。 这一切都是因为DeepSeek R1的发布。1月20日，DeepSeek正式发布性能比肩OpenAI o1完整版的R1推理模型后，直接带动大模型行业的研究焦点，从之前 的GPT模式，转向了Reasoner模式。 梁文锋和DeepSeek R1的到来，将新的AI时代切割成由两大milestones（里程碑）节点分割而来的两段不同时期： 一个是ChatGPT的问世，一个是DeepSeek R1新模型的发布。身处不同节点 ...

2025年上半年，大部分合资车企通过"一口价"模式，加强自家燃油车的价格竞争力，其中不乏传统豪华品牌。作为一线豪华品牌的奥迪也是下了狠手，电 影《飞驰人生2》主角车型奥迪A3，新款的价格已经打到了13万元左右的价格带。 给持续降价打了个幌子 "不用讨价还价，没有套路，奥迪A3限时一口价12.49万元起""奥迪A3低配贷款落地15万元，中配贷款落地16万元"。进入5月，不少奥迪4S店的销售在社 交媒体上吆喝了起来。 "奥迪的轿车都已经这么便宜了？"虽然有些消费者一开始抱有怀疑态度，但是当看到各路4S店官方账号上放出的正式价格海报，也不禁感叹和调侃"奥迪 这是卖出了奥拓的价格"。 目前在售的2025款奥迪A3同时提供两厢版和长轴距三厢版车型，其中两厢车型A3 Sportback共有"飞驰悦享型""飞驰尊享型"以及"飞驰尊享型+豪华臻选 包"3款车型，官方指导价分别为16.59万元、18.99万元和20.59万元，三厢车型A3L Limousine也有同样的3款车型，官方指导价分别为16.99万元、19.39万 元和20.99万元。 在天津某奥迪4S店的宣传海报上，A3 Sportback降价后的"限时一口价"分别 ...

Core Insights - The Chinese passenger car market experienced a significant structural price adjustment in the first four months of 2025, with a total retail of 6.872 million units, reflecting a year-on-year growth of 7.9% [1] - The average price of passenger cars in 2025 was 170,000 yuan, a decrease of 7000 yuan compared to 2024, with April 2025 showing a decline of 21,000 yuan year-on-year, marking the largest drop in nearly five years [1] Market Dynamics - The decline in prices is attributed to the increase in entry-level model sales due to government subsidies for scrapping and replacing old vehicles, leading to a shift in consumer preference towards mid-to-low-priced vehicles [1] - The penetration rate of new energy vehicles (NEVs) in the market below 50,000 yuan reached 90% in April 2025, with pure electric models accounting for 86% of this segment [2] - In the high-end market (above 300,000 yuan), NEVs accounted for approximately 40%, with range-extended models being more prevalent than pure electric and hybrid models [2] Brand Performance - In the first four months of 2025, luxury brands maintained an average price of 366,000 yuan, while joint venture brands saw a slight increase to 174,000 yuan [3] - New force brands experienced a significant price drop of 36,000 yuan to 235,000 yuan, and domestic brands slightly decreased to 121,000 yuan [3] - Notably, the average price of NEVs across luxury, joint venture, and domestic brands surpassed that of their fuel counterparts, indicating a strong market position for NEV products [3]

Core Viewpoint - The drastic price drop of the 23-valent pneumococcal polysaccharide vaccine has severely impacted the profitability of companies in the vaccine industry, leading to an intensified price war and a challenging market environment [1][3][5]. Group 1: Price Drop and Market Impact - The procurement results for the 23-valent pneumococcal vaccine revealed a shocking price of 25 yuan per dose, a nearly 90% decrease from the previous market price of approximately 200 yuan [1]. - This price drop has pushed the industry into a fierce price war, with companies like Beijing Kexing and Yuxi Watson winning bids at significantly lower prices [1][2]. - The trend of price reduction is not new, but the current situation marks a historical low for government procurement projects [1]. Group 2: Government Policies and Vaccination Rates - The vaccination rate for adults, particularly among the elderly in cities like Guangzhou, remains low, with only 14.13% coverage [2]. - To improve vaccination coverage, many local governments have included second-class vaccines in free vaccination programs, further pressuring companies to accept lower prices [2]. - The trend of "volume for price" in government procurement is expected to continue, leading to further price declines in the industry [2]. Group 3: Industry Challenges and Profitability - The vaccine industry is facing collective difficulties, with a projected 34% year-on-year decline in the issuance of 23-valent pneumococcal vaccines in 2024 [3]. - Major companies like Watson Bio and Zhifei Biological are experiencing significant drops in sales, with Watson reporting a 20.21% decrease in overall product sales [3]. - The strategy of "low price for market share" has backfired, as many companies report net profit declines exceeding 30% [3]. Group 4: Policy Changes and Future Outlook - The National Health Commission has indicated plans to dynamically adjust immunization strategies, potentially including necessary vaccines in the national immunization program, which could lead to a recovery in sales but not in prices [4]. - Companies are urged to transform their business models, as reliance on low prices may not sustain long-term competitiveness [4]. - Analysts suggest that companies with scalable production capabilities and innovative pipelines will have a better chance of survival in the evolving market [4]. Group 5: Conclusion on Market Dynamics - The dramatic price reduction from 200 yuan to 25 yuan signifies the end of the "price myth" for pneumococcal vaccines, driven by policy changes and market dynamics [5]. - Companies must find a balance in cost control, technological innovation, and diversified strategies to survive the current market challenges [5]. - The industry must focus on technological upgrades and value reconstruction to escape the "price for volume" dilemma [5].